A modified Delphi panel to establish a threshold of meaningful progression on MDS-UPDRS Part III
Objective: To establish a threshold for meaningful progression on MDS-UPDRS Part III in an early-stage Parkinson's disease (PD) population (Hoehn & Yahr [H&Y] Stage I–II)…The STEPWISE Parkinson study: a Smartphone Based Exercise Solution for Patients With Parkinson’s Disease
Objective: To investigate the feasibility of a smartphone app (STEPWISE app) to increase the physical activity level (i.e. number of steps) in people with Parkinson’s…Improving the design of clinical trials in early-stage Parkinson’s disease by using the estimand framework
Objective: To show how the estimand framework can be used to improve design of clinical trials testing treatments in early-stage Parkinson’s disease (PD). Background: The…Effect of exercise on brain metabolism and energetics in PD
Objective: To identity the effect of exercise on brain metabolism and energetics in PD using PET/MR imaging. Background: Aerobic exercise slows PD progression as reflected…NONINVASIVE BRAINSTEM MODULATION FOR THE TREATMENT OF NONMOTOR SYMPTOMS IN PARKINSON’S DISEASE: A RANDOMIZED CONTROLLED TRIAL AND OPEN LABEL EXTENSION STUDY
Objective: A multi-site double-blinded pivotal randomized controlled trial (RCT) with an open label extension (OLE) study has been initiated to evaluate the safety and efficacy…Time-to-event approach mitigates the treatment masking effect of symptomatics on MDS-UPDRS Part III
Objective: To assess whether a time-to-event (TTE) approach may mitigate the masking effect of changing symptomatic therapy on Movement Disorders Society–Unified Parkinson’s Disease (PD) Rating…Parkinson`s disease in Pandemic Covid
Objective: SARS-CoV2 infection invades the brain through ACE2 receptors or the cytotoxic aggregation of proteins, including α-synuclein.Studies are uncertain on the risk of COVID and…Yoga for Functional Neurological Disorder (FND) – A Case Study
Objective: To describe key components of a yoga program for an individual with FND and evaluate feasibility and efficacy. Background: FND is the second most…Liraglutide once daily versus placebo in Parkinson’s disease: a randomized, double-blind, placebo-controlled trial
Objective: To test safety and efficacy of the glucagon-like peptide 1 (GLP-1) agonist liraglutide in idiopathic Parkinson’s disease (PD). Background: Insulin resistance (IR) may play…A motor-cognitive intervention impacts daily-living gait and activity in Parkinson’s disease fallers differently than a motor intervention: analysis using a machine learning approach
Objective: Applying machine learning (ML) to identify if there were clusters of daily-living gait and physical activity measures that differed among responders to the two…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 23
- Next Page »